BeiGene, Ltd. (ONC)vsRigel Pharmaceuticals Inc (RIGL)
ONC
BeiGene, Ltd.
$283.45
+2.81%
HEALTHCARE · Cap: $31.62B
RIGL
Rigel Pharmaceuticals Inc
$26.29
+0.61%
HEALTHCARE · Cap: $489.54M
Smart Verdict
WallStSmart Research — data-driven comparison
BeiGene, Ltd. generates 1716% more annual revenue ($5.34B vs $294.28M). RIGL leads profitability with a 124.7% profit margin vs 5.4%. RIGL trades at a lower P/E of 1.4x. RIGL earns a higher WallStSmart Score of 79/100 (B+).
ONC
Hold42
out of 100
Grade: D
RIGL
Strong Buy79
out of 100
Grade: B+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-1983.5%
Fair Value
$16.86
Current Price
$283.45
$266.59 premium
Margin of Safety
+96.2%
Fair Value
$911.66
Current Price
$26.29
$885.37 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 32.8% year-over-year
Conservative balance sheet, low leverage
Attractively priced relative to earnings
Reasonable price relative to book value
Keeps 125 of every $100 in revenue as profit
Strong operational efficiency at 33.2%
Revenue surging 21.2% year-over-year
Areas to Watch
0.0% earnings growth
ROE of 7.5% — below average capital efficiency
5.4% margin — thin
Premium valuation, high expectations priced in
Smaller company, higher risk/reward
ROE of 1.9% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ONC
The strongest argument for ONC centers on Revenue Growth, Debt/Equity. Revenue growth of 32.8% demonstrates continued momentum.
Bull Case : RIGL
The strongest argument for RIGL centers on P/E Ratio, Price/Book, Profit Margin. Profitability is solid with margins at 124.7% and operating margin at 33.2%. Revenue growth of 21.2% demonstrates continued momentum.
Bear Case : ONC
The primary concerns for ONC are EPS Growth, Return on Equity, Profit Margin. A P/E of 111.0x leaves little room for execution misses.
Bear Case : RIGL
The primary concerns for RIGL are Market Cap, Return on Equity.
Key Dynamics to Monitor
ONC profiles as a hypergrowth stock while RIGL is a growth play — different risk/reward profiles.
RIGL carries more volatility with a beta of 1.17 — expect wider price swings.
ONC is growing revenue faster at 32.8% — sustainability is the question.
ONC generates stronger free cash flow (131M), providing more financial flexibility.
Bottom Line
RIGL scores higher overall (79/100 vs 42/100), backed by strong 124.7% margins and 21.2% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
BeiGene, Ltd.
HEALTHCARE · BIOTECHNOLOGY · USA
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company is headquartered in Camana Bay, the Cayman Islands.
Visit Website →Rigel Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat blood disorders, cancer, and rare immune diseases. The company is headquartered in South San Francisco, California.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?